Scarica l'app Stockscreener
2.59
1.17%
0.03
Pre-mercato:
2.60
0.01
+0.39%
Precedente Chiudi:
$2.56
Aprire:
$2.58
Volume 24 ore:
563.44K
Relative Volume:
0.48
Capitalizzazione di mercato:
$147.57M
Reddito:
-
Utile/perdita netta:
$-82.44M
Rapporto P/E:
-1.3777
EPS:
-1.88
Flusso di cassa netto:
$-66.75M
1 W Prestazione:
+7.92%
1M Prestazione:
+0.00%
6M Prestazione:
-12.79%
1 anno Prestazione:
+5.71%
Intervallo 1D:
$2.55
$2.65
Intervallo di 1 settimana:
$2.405
$2.70
Portata 52W:
$1.195
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Nome
Black Diamond Therapeutics Inc
Settore
Industria
Telefono
617-417-5868
Indirizzo
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Confronta BDTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.59 | 145.86M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-11-18 | Ripresa | Piper Sandler | Overweight |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-07-01 | Ripresa | Raymond James | Outperform |
| 2024-07-31 | Iniziato | Raymond James | Outperform |
| 2023-07-14 | Iniziato | Piper Sandler | Overweight |
| 2023-06-30 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-03-29 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-03-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | Iniziato | Stifel | Hold |
| 2021-01-07 | Iniziato | Wedbush | Outperform |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | Canaccord Genuity | Buy |
| 2020-02-24 | Iniziato | Cowen | Outperform |
| 2020-02-24 | Iniziato | JP Morgan | Overweight |
| 2020-02-24 | Iniziato | Jefferies | Buy |
Mostra tutto
Black Diamond Therapeutics Inc Borsa (BDTX) Ultime notizie
Entry Recap: Can Black Diamond Therapeutics Inc maintain sales growthRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Reactions: Does Black Diamond Therapeutics Inc outperform in volatile markets2025 Key Highlights & Expert Approved Trade Ideas - baoquankhu1.vn
Growth Review: Is Black Diamond Therapeutics Inc stock good for income investorsEarnings Beat & High Conviction Trade Alerts - baoquankhu1.vn
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aug Patterns: Does Black Diamond Therapeutics Inc outperform in volatile marketsJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Market Review: Whats the profit margin of Black Diamond Therapeutics IncEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Down 39.9% in December - Defense World
Piper Sandler Maintains Rating but Lowers Price Target for BDTX | BDTX Stock News - GuruFocus
Declining Stock and Solid Fundamentals: Is The Market Wrong About Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)? - Yahoo Finance
Growth Value: What is the long term forecast for MPLX LP Limited Partnership stockJuly 2025 Big Picture & Weekly Chart Analysis and Guides - baoquankhu1.vn
Is Research Solutions Inc stock technically oversoldJuly 2025 Market Mood & Reliable Volume Spike Alerts - baoquankhu1.vn
Profit Recap: Is Black Diamond Therapeutics Inc forming a bullish divergenceMarket Sentiment Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
Growth Review: Can VSTEW sustain its profitabilityTrade Exit Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Jobs Data: Why Black Diamond Therapeutics Inc stock could outperform in 2025Earnings Recap Report & Real-Time Volume Surge Alerts - Bộ Nội Vụ
Black Diamond Therapeutics (NASDAQ:BDTX) Upgraded at Zacks Research - Defense World
What margin trends mean for Black Diamond Therapeutics Inc. stockFootwear buying guidance for urban daily use on hard surfaces focuses on foot fatigue reduction, making it designed for long term daily comfort. - ulpravda.ru
Published on: 2026-01-11 01:14:22 - Улправда
Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - simplywall.st
Black Diamond Therapeutics (NASDAQ:BDTX) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
What Makes Black Diamond (BDTX) a New Strong Buy Stock - sharewise.com
New Strong Buy Stocks for January 9th - Yahoo Finance
Why Black Diamond Therapeutics Inc. stock could benefit from AI revolution2025 Sector Review & Real-Time Stock Price Movement Reports - Улправда
Is Black Diamond Therapeutics Inc. stock supported by innovation pipelineProduct Launch & AI Powered Buy/Sell Recommendations - Улправда
สล็อต - Early Times
Evoke Pharma Leads Stock Performance with 148.87% Return in Pharmaceuticals Sector - Markets Mojo
Black Diamond Therapeutics’ Silevertinib shows 60% response rate in preliminary phase 2 lung cancer data - MSN
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Insider Monkey
Black Diamond Therapeutics' Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Finviz
What analysts say about Black Diamond Therapeutics Inc stockCandlestick Trading Patterns & High Return Trading Ideas - earlytimes.in
Would You Still Hold Black Diamond Therapeutics Stock If It Fell Another 30%? - Trefis
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to NASDAQ Biotechnology Index - marketscreener.com
BDTX (Black Diamond Therapeutics) EV-to-OCF : 1.30 (As of Dec. 21, 2025) - GuruFocus
Can Black Diamond Therapeutics Inc. stock deliver strong Q4 earnings2025 Institutional Moves & Daily Market Momentum Tracking - DonanımHaber
Can Black Diamond Therapeutics Inc. stock withstand economic slowdown2025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
What momentum indicators show for Black Diamond Therapeutics Inc. stockWeekly Stock Summary & Accurate Trade Setup Notifications - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Cullinan Management (CGEM) - The Globe and Mail
Black Diamond Therapeutics (BDTX) director receives 4,665 share award - Stock Titan
Black Diamond Therapeutics (BDTX) – Analysts’ Weekly Ratings Updates - Defense World
A strong week for data readouts: Clinical Report - BioCentury
Can Black Diamond Therapeutics (BDTX) Turn Silevertinib’s Dual-Cancer Ambition Into a Cohesive Strategy? - Yahoo Finance
Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) - sharewise.com
Can Black Diamond Therapeutics Inc. stock continue upward trendGap Down & Long-Term Investment Growth Plans - Newser
Will Black Diamond Therapeutics Inc. stock attract more institutional investorsInsider Selling & Technical Pattern Based Buy Signals - Newser
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Lowered by Guggenheim - MarketBeat
Stifel reiterates Buy rating on Black Diamond Therapeutics stock at $8 - Investing.com Australia
Black Diamond Therapeutics Inc Azioni (BDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):